Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, Topics

Altimmune Topline Ph2 Pemvidutide MASH Data

Here is a brief preview of this blast: Altimmune announced topline 48-week results from its Ph2b IMPACT study investigating the safety and efficacy of pemvidutide (1.2/1.8mg; QW SC GLP-1/GCG dual receptor agonist), compared to placebo, in patients with F2-F3 MASH (view CT.gov record). An associated call was held (view slides). Of note, the company’s stock is down ~20% following the readout. Below, FENIX provides insights and highlights from the 48-week data.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.